R Weinshilboum

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression
    Mohan Liu
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mol Endocrinol 27:657-70. 2013
  2. ncbi Interview: Richard M Weinshilboum talks to Hannah Branch, Assistant Commissioning Editor
    Richard M Weinshilboum
    Mayo Foundation Rochester, Division of Pharmacology, 200 First Street, SW Rochester, MN 55905, USA
    Biomark Med 7:5-10. 2013
  3. ncbi Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression
    Mohan Liu
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Breast Cancer Res 14:R41. 2012
  4. ncbi Human liver methionine cycle: MAT1A and GNMT gene resequencing, functional genomics, and hepatic genotype-phenotype correlation
    Yuan Ji
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA
    Drug Metab Dispos 40:1984-92. 2012
  5. ncbi Interview: An interview with Pharmacogenomics for the breast cancer special focus issue
    Richard M Weinshilboum
    Mayo Foundation Rochester, Division of Clinical Pharmacology, 200 First Street, SW Rochester, MN 55905, USA
    Pharmacogenomics 13:655-8. 2012
  6. ncbi Pharmacogenetics and pharmacogenomics: development, science, and translation
    Richard M Weinshilboum
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Mayo Medical School Mayo Foundation, Rochester, Minnesota 55905, USA
    Annu Rev Genomics Hum Genet 7:223-45. 2006
  7. ncbi Pharmacogenomics: catechol O-methyltransferase to thiopurine S-methyltransferase
    Richard M Weinshilboum
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cell Mol Neurobiol 26:539-61. 2006
  8. ncbi Pharmacogenomics of endocrine therapy in breast cancer
    Richard Weinshilboum
    Mayo Clinic College of Medicine, Mayo Clinic, Mayo Foundation, Rochester, MN 55905, USA
    Adv Exp Med Biol 630:220-31. 2008
  9. ncbi Pharmacogenomics: bench to bedside
    Richard Weinshilboum
    Mayo Medical School Mayo Graduate School, Mayo Clinic College of Medicine, Department of Molecular Pharmacology and Experimental Therapeutics, Rochester, Minnesota 55905, USA
    Nat Rev Drug Discov 3:739-48. 2004
  10. ncbi Inheritance and drug response
    Richard Weinshilboum
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School, Mayo Clinic, and Mayo Foundation, Rochester, Minn 55905, USA
    N Engl J Med 348:529-37. 2003

Research Grants

  1. INHERITED VARIATIONS IN DRUG METABOLIZING ENZYMES
    Richard Weinshilboum; Fiscal Year: 2009
  2. Pharmacogenomics of cytosine arabinoside (Ara-C) and acute myelogenous leukemia
    Richard Weinshilboum; Fiscal Year: 2009
  3. INHERITED VARIATIONS IN DRUG METABOLIZING ENZYMES
    Richard M Weinshilboum; Fiscal Year: 2010
  4. SULFATE CONJUGATION AND DRUG METABOLISM
    Richard Weinshilboum; Fiscal Year: 2003
  5. INHERITED VARIATIONS IN DRUG METABOLIZING ENZYMES
    Richard Weinshilboum; Fiscal Year: 2002
  6. Pharmacogenomics of cytosine arabinoside (Ara-C) and acute myelogenous leukemia
    Richard M Weinshilboum; Fiscal Year: 2010
  7. INHERITED VARIATIONS IN DRUG METABOLIZING ENZYMES
    Richard Weinshilboum; Fiscal Year: 2007
  8. PHARMACOGENETICS OF PHASE II DRUG METABOLIZING ENZYMES
    Richard Weinshilboum; Fiscal Year: 2007
  9. TRAINING GRANT IN CLINICAL PHARMACOLOGY
    Richard Weinshilboum; Fiscal Year: 2007
  10. SULFATE CONJUGATION AND DRUG METABOLISM
    Richard Weinshilboum; Fiscal Year: 2007

Detail Information

Publications76

  1. ncbi TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression
    Mohan Liu
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mol Endocrinol 27:657-70. 2013
    ..TSPYL5 induced CYP19A1 expression and that of many other genes. These studies have revealed a novel mechanism for regulating aromatase expression and plasma E2 concentrations in postmenopausal women with ER(+) breast cancer...
  2. ncbi Interview: Richard M Weinshilboum talks to Hannah Branch, Assistant Commissioning Editor
    Richard M Weinshilboum
    Mayo Foundation Rochester, Division of Pharmacology, 200 First Street, SW Rochester, MN 55905, USA
    Biomark Med 7:5-10. 2013
    ..Another major component of Pharmacogenetics of Phase II Drug Metabolizing Enzymes activities involves the systematic 'translation' of this pharmacogenomic information to the bedside...
  3. ncbi Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression
    Mohan Liu
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Breast Cancer Res 14:R41. 2012
    ..In the present study, we set out to determine whether these SNPs might influence cytokine expression and effect more widely, and, if so, to explore the mechanism of TCL1A-related AI-induced side effects...
  4. ncbi Human liver methionine cycle: MAT1A and GNMT gene resequencing, functional genomics, and hepatic genotype-phenotype correlation
    Yuan Ji
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA
    Drug Metab Dispos 40:1984-92. 2012
    ....
  5. ncbi Interview: An interview with Pharmacogenomics for the breast cancer special focus issue
    Richard M Weinshilboum
    Mayo Foundation Rochester, Division of Clinical Pharmacology, 200 First Street, SW Rochester, MN 55905, USA
    Pharmacogenomics 13:655-8. 2012
    ..Another major component of Phase II Drug Metabolizing Enzymes activities involves the systematic 'translation' of this pharmacogenomic information to the bedside...
  6. ncbi Pharmacogenetics and pharmacogenomics: development, science, and translation
    Richard M Weinshilboum
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Mayo Medical School Mayo Foundation, Rochester, Minnesota 55905, USA
    Annu Rev Genomics Hum Genet 7:223-45. 2006
    ..However, significant challenges remain to be overcome if pharmacogenetics-pharmacogenomics is to achieve its full potential as a major medical application of genomic science...
  7. ncbi Pharmacogenomics: catechol O-methyltransferase to thiopurine S-methyltransferase
    Richard M Weinshilboum
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cell Mol Neurobiol 26:539-61. 2006
    ....
  8. ncbi Pharmacogenomics of endocrine therapy in breast cancer
    Richard Weinshilboum
    Mayo Clinic College of Medicine, Mayo Clinic, Mayo Foundation, Rochester, MN 55905, USA
    Adv Exp Med Biol 630:220-31. 2008
    ..Those results-together with our current level of understanding of tamoxifen pharmacogenomics-will be reviewed in this chapter and both will be placed within the context of the overall development of pharmacogenomics...
  9. ncbi Pharmacogenomics: bench to bedside
    Richard Weinshilboum
    Mayo Medical School Mayo Graduate School, Mayo Clinic College of Medicine, Department of Molecular Pharmacology and Experimental Therapeutics, Rochester, Minnesota 55905, USA
    Nat Rev Drug Discov 3:739-48. 2004
    ....
  10. ncbi Inheritance and drug response
    Richard Weinshilboum
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School, Mayo Clinic, and Mayo Foundation, Rochester, Minn 55905, USA
    N Engl J Med 348:529-37. 2003
  11. ncbi Pharmacogenetics: inherited variation in amino acid sequence and altered protein quantity
    Richard Weinshilboum
    Department of Molecular Pharmacology and Experimental Therapeutics and Medicine, Mayo Medical School-Mayo Clinic-Mayo Foundation, Rochester, MN 55905, USA
    Clin Pharmacol Ther 75:253-8. 2004
  12. ncbi Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase
    R M Weinshilboum
    Department of Pharmacology, Mayo Medical School Mayo Clinic Mayo Foundation, Rochester, Minnesota 55905, USA
    Annu Rev Pharmacol Toxicol 39:19-52. 1999
    ....
  13. ncbi Copy number variation and cytidine analogue cytotoxicity: a genome-wide association approach
    Krishna R Kalari
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA
    BMC Genomics 11:357. 2010
    ..In the present study, we set out to test the hypothesis that variation in copy number might contribute to variation in cytidine analogue response phenotypes...
  14. ncbi The Gordon Wilson Lecture. The Mayo model: one path to an academic medical center
    Richard M Weinshilboum
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School-Mayo Clinic-Mayo Foundation, Rochester, MN 55905, USA
    Trans Am Clin Climatol Assoc 113:91-103; discussion 103-6. 2002
  15. ncbi Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase
    R Weinshilboum
    Department of Pharmacology, Mayo Medical School Mayo Graduate School Mayo Clinic, Rochester, Minnesota 55905, USA
    Drug Metab Dispos 29:601-5. 2001
    ..As a result of these observations, the TPMT genetic polymorphism represents a model system for the way in which basic pharmacogenetic information is developed and applied to clinical medicine...
  16. ncbi Methylenetetrahydrofolate reductase haplotype tag single-nucleotide polymorphisms and risk of breast cancer
    Yvette N Martin
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 15:2322-4. 2006
  17. ncbi Canine red blood cell thiopurine S-methyltransferase: companion animal pharmacogenetics
    Oreste E Salavaggione
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School Mayo Clinic Mayo Foundation, Rochester, Minnesota 55905, USA
    Pharmacogenetics 12:713-24. 2002
    ..These observations represent a step towards the application of pharmacogenetic and pharmacogenomic principles to companion animal drug therapy...
  18. ncbi Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms
    D Otterness
    Department of Pharmacology, Mayo Medical School Mayo Clinic Mayo Foundation, Rochester, MN 55905, USA
    Clin Pharmacol Ther 62:60-73. 1997
    ..Characterization of variant alleles for low TPMT enzyme activity will help make it possible to assess the potential clinical utility of deoxyribonucleic acid-based diagnostic tests for determining TPMT genotype...
  19. ncbi Human arsenic methyltransferase (AS3MT) pharmacogenetics: gene resequencing and functional genomics studies
    Thomas C Wood
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    J Biol Chem 281:7364-73. 2006
    ..These results raise the possibility that inherited variation in AS3MT may contribute to variation in arsenic metabolism and, perhaps, arsenic-dependent carcinogenesis in humans...
  20. ncbi Human phenylethanolamine N-methyltransferase pharmacogenomics: gene re-sequencing and functional genomics
    Yuan Ji
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    J Neurochem 95:1766-76. 2005
    ..These observations raise the possibility of inherited variation in the ability to form epinephrine from norepinephrine as a result of variant PNMT polymorphisms and haplotypes...
  21. ncbi CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
    Yan Jin
    Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    J Natl Cancer Inst 97:30-9. 2005
    ....
  22. ncbi Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions
    L Wang
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Oncogene 25:1629-38. 2006
    ....
  23. ncbi Human methylenetetrahydrofolate reductase pharmacogenomics: gene resequencing and functional genomics
    Yvette N Martin
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Pharmacogenet Genomics 16:265-77. 2006
    ..These observations represent steps towards an understanding of molecular genetic mechanisms responsible for variation in MTHFR function that may contribute to individual differences in drug efficacy and toxicity, as well as disease risk...
  24. ncbi Coprescription of tamoxifen and medications that inhibit CYP2D6
    Kostandinos Sideras
    Department of Oncology, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA
    J Clin Oncol 28:2768-76. 2010
    ....
  25. ncbi Catechol O-methyltransferase pharmacogenomics: human liver genotype-phenotype correlation and proximal promoter studies
    Jianping Zhang
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Pharmacogenet Genomics 19:577-87. 2009
    ..We set out to test the hypothesis that additional COMT polymorphisms might also be associated with phenotypic variation...
  26. ncbi Human aromatase: gene resequencing and functional genomics
    Cynthia X Ma
    Department of Medical Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer Res 65:11071-82. 2005
    ..These observations indicate that genetic variation in CYP19 might contribute to variation in the pathophysiology of estrogen-dependent disease...
  27. ncbi Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers
    Liang Li
    Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA
    PLoS ONE 4:e7765. 2009
    ....
  28. ncbi Cat red blood cell thiopurine S-methyltransferase: companion animal pharmacogenetics
    Oreste E Salavaggione
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School, Mayo Clinic Mayo Foundation, Rochester, MN 55905, USA
    J Pharmacol Exp Ther 308:617-26. 2004
    ..They also represent a step toward the application of pharmacogenetic principles to companion animal thiopurine drug therapy...
  29. ncbi A comprehensive examination of CYP19 variation and breast density
    Janet E Olson
    Division of Epidemiology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55901, USA
    Cancer Epidemiol Biomarkers Prev 16:623-5. 2007
  30. ncbi Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248
    Steven R Alberts
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Clin Colorectal Cancer 6:572-7. 2007
    ..A phase I trial was performed to establish the maximum tolerated dose (MTD) of pemetrexed and oxaliplatin when B(12) and folate supplementation is used...
  31. ncbi Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics
    Neslihan Aygun Kocabas
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Drug Metab Dispos 36:1951-9. 2008
    ..These gene sequence differences may contribute to variations in the metabolic activation of gemcitabine and other cytidine antimetabolites...
  32. ncbi Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance
    Matthew P Goetz
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 14:5864-8. 2008
    ..We sought to determine the combined effect of inherited (CYP2D6) and somatic (HOXB13/IL17BR) gene variation in tamoxifen-treated breast cancer...
  33. ncbi Cardiovascular pharmacogenomics and individualized drug therapy
    Naveen L Pereira
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Nat Rev Cardiol 6:632-8. 2009
    ..This article reviews the development, promise and challenges facing pharmacogenomics, using examples of drugs used to treat or prevent cardiovascular disease...
  34. ncbi Glutathione pathway genetic polymorphisms and lung cancer survival after platinum-based chemotherapy
    Ann M Moyer
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 19:811-21. 2010
    ..We set out to test the hypotheses that single nucleotide polymorphisms (SNPs) or copy number polymorphisms for genes within the glutathione pathway might influence survival in lung cancer patients treated with these drugs...
  35. ncbi Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors
    Liewei Wang
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 70:319-28. 2010
    ..Our findings indicate that two common genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to aromatase inhibitors...
  36. ncbi Natriuretic peptide pharmacogenetics: membrane metallo-endopeptidase (MME): common gene sequence variation, functional characterization and degradation
    Naveen L Pereira
    Division of Cardiovascular Diseases and Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Mol Cell Cardiol 49:864-74. 2010
    ..This polymorphism could have a significant effect on the metabolism of natriuretic peptides...
  37. ncbi The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
    Matthew P Goetz
    Department of Oncology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN, 55905, USA
    Breast Cancer Res Treat 101:113-21. 2007
    ....
  38. ncbi A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches
    Janet E Olson
    Department of Health Sciences Research, Division of Epidemiology, Mayo Clinic College of Medicine, Rochester, MN 55901, USA
    Breast Cancer Res Treat 102:237-47. 2007
    ..We recently published resequencing data on 88 polymorphisms identified in that gene. The hypothesis tested in this study was that polymorphisms, or haplotypes, in CYP19 are related to risk of breast cancer...
  39. ncbi Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors
    James N Ingle
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 28:4674-82. 2010
    ....
  40. ncbi Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer
    James N Ingle
    Division of Medical Oncology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 70:3278-86. 2010
    ..These findings may have implications with regard to efficacy and adverse events and may indicate the need to "individualize" therapy with this drug...
  41. ncbi CYP2C19 variation and citalopram response
    David A Mrazek
    Department of Psychiatry and Psychology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Pharmacogenet Genomics 21:1-9. 2011
    ..Citalopram is metabolized by three CYP enzymes. CYP2C19 and CYP3A4 play a primary role in citalopram metabolism, whereas CYP2D6 plays a secondary role...
  42. ncbi Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review
    Ping Yang
    Division of Epidemiology and Cancer Center, Nicotine Dependence Center, and Department of Molecular Pharmacology and Experimental Therapeutics, Rochester, MN 55905, USA
    J Clin Oncol 24:1761-9. 2006
    ..The potential application of glutathione system polymorphic genetic markers in identifying patients who may respond favorably, selecting effective antitumor drugs, and balancing drug efficacy and toxicity are discussed...
  43. ncbi Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics
    Judith A Gilbert
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 12:1794-803. 2006
    ..Gemcitabine metabolic inactivation is catalyzed by cytidine deaminase (CDA) or, after phosphorylation, by deoxycytidylate deaminase (DCTD). We set out to study the pharmacogenomics of CDA and DCTD...
  44. ncbi Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation
    Liewei Wang
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Proc Natl Acad Sci U S A 102:9394-9. 2005
    ..The results of these experiments provide insight into a unique pharmacogenetic mechanism by which common polymorphisms affect TPMT protein function and, as a result, therapeutic response to thiopurine drugs...
  45. ncbi Human SULT1A3 pharmacogenetics: gene duplication and functional genomic studies
    Michelle A T Hildebrandt
    Department of Molecular Pharmacology, Mayo Clinic College of Medicine, Mayo Foundation, Rochester, MN 55905, USA
    Biochem Biophys Res Commun 321:870-8. 2004
    ..The duplication of SULT1A3 will have to be taken into account in future efforts to understand individual variation in SULT1A3 activity or properties...
  46. ncbi Human phenylethanolamine N-methyltransferase genetic polymorphisms and exercise-induced epinephrine release
    Yuan Ji
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Mayo Foundation, Rochester, Minnesota 55905, USA
    Physiol Genomics 33:323-32. 2008
    ..Our studies suggest that functionally significant variant sequence in the human PNMT gene might contribute to individual variation in levels of circulating epinephrine during exercise...
  47. ncbi Human 3'-phosphoadenosine 5'-phosphosulfate synthetase 2 (PAPSS2) pharmacogenetics: gene resequencing, genetic polymorphisms and functional characterization of variant allozymes
    Zhen Hua Xu
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School Mayo Clinic Mayo Foundation, Rochester, MN 55905, USA
    Pharmacogenetics 12:11-21. 2002
    ..It will now be possible to test the hypothesis that these common, functionally significant PAPSS2 genetic polymorphisms might contribute to variations in sulfate conjugation in vivo...
  48. ncbi Glutathione S-transferase omega 1 and omega 2 pharmacogenomics
    Baidehi Mukherjee
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Drug Metab Dispos 34:1237-46. 2006
    ..These observations raise the possibility of functionally significant pharmacogenomic variation in the expression and function of GSTO1 and GSTO2...
  49. ncbi Human hydroxysteroid sulfotransferase SULT2B1 pharmacogenomics: gene sequence variation and functional genomics
    Yuan Ji
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Pharmacol Exp Ther 322:529-40. 2007
    ..These studies resulted in the identification of common SULT2B1 gene sequence variation, as well as insight into the effects of that variation on the function of this important steroid-metabolizing enzyme...
  50. ncbi CD38 expression, function, and gene resequencing in a human lymphoblastoid cell line-based model system
    William R Hartman
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 51:1315-25. 2010
    ..We also determined that variation in CD38 expression in these cell lines was associated with variation in antineoplastic drug sensitivity. These results represent a step toward understanding mechanisms involved in CD38 expression...
  51. ncbi Cytosolic 5'-nucleotidase III (NT5C3): gene sequence variation and functional genomics
    Pinar Aksoy
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Pharmacogenet Genomics 19:567-76. 2009
    ..One gene that was significantly associated with gemcitabine cytotoxicity was a nucleotidase family member, NT5C3. Very little is known with regard to the pharmacogenomics of this family of enzymes...
  52. ncbi Human histamine N-methyltransferase gene: structural characterization and chromosomal location
    S Aksoy
    Department of Pharmacology, Mayo Medical School, Mayo Foundation, Rochester, Minnesota 55905, USA
    Biochem Biophys Res Commun 219:548-54. 1996
    ..HNMT mapped to human chromosome 2. Structural characterization of the gene for HNMT will make it possible to study molecular genetic mechanisms involved in the regulation of this important enzyme in humans...
  53. ncbi Thiopurine S-methyltransferase pharmacogenetics: functional characterization of a novel rapidly degraded variant allozyme
    Qiping Feng
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic Mayo Medical School, 200 First Street SW, Rochester, MN 55905, United States
    Biochem Pharmacol 79:1053-61. 2010
    ..In summary, TPMT*27 serves to illustrate the potential importance of protein degradation - both proteasome and autophagy-mediated degradation - for the pharmacogenetic effects of nonsynonymous SNPs...
  54. ncbi Human catecholamine sulfotransferase (SULT1A3) pharmacogenetics: functional genetic polymorphism
    Bianca A Thomae
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School Mayo Clinic, Rochester, Minnesota 55905, USA
    J Neurochem 87:809-19. 2003
    ..These observations raise the possibility of ethnic-specific inherited alterations in catecholamine sulfation in humans...
  55. ncbi Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics
    Oreste E Salavaggione
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine Mayo Clinic, Rochester, Minnesota 55905, USA
    Pharmacogenet Genomics 15:801-15. 2005
    ..These studies indicate that a common mechanism responsible for alterations in the activity of variant TPMT allozymes involves alteration in the level of enzyme protein due, at least in part, to accelerated degradation...
  56. ncbi Human estrogen sulfotransferase (SULT1E1) pharmacogenomics: gene resequencing and functional genomics
    Araba A Adjei
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School-Mayo Clinic-Mayo Foundation, Rochester, MN 55905, U.S.A
    Br J Pharmacol 139:1373-82. 2003
    ....
  57. ncbi Glutathione s-transferase p1: gene sequence variation and functional genomic studies
    Ann M Moyer
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School Mayo Clinic, Rochester, Minnesota, USA
    Cancer Res 68:4791-801. 2008
    ....
  58. ncbi Glutathione S-transferase T1 and M1: gene sequence variation and functional genomics
    Ann M Moyer
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 13:7207-16. 2007
    ..We set out to systematically identify common polymorphisms in GSTT1 and GSTM1, followed by functional genomic studies...
  59. ncbi Human betaine-homocysteine methyltransferase (BHMT) and BHMT2: common gene sequence variation and functional characterization
    Fang Li
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Mol Genet Metab 94:326-35. 2008
    ..These studies have defined common genetic variation in BHMT and BHMT2 and functionally characterized BHMT SNPs. They may also help to explain why BHMT2 has not previously been defined functionally...
  60. ncbi Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism
    C Szumlanski
    Department of Pharmacology, Mayo Medical School, Rochester, MN 55905, USA
    DNA Cell Biol 15:17-30. 1996
    ....
  61. ncbi Aggresome formation and pharmacogenetics: sulfotransferase 1A3 as a model system
    Liewei Wang
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School-Mayo Clinic-Mayo Foundation, Rochester, MN 55905, USA
    Biochem Biophys Res Commun 325:426-33. 2004
    ..The possible role of aggresome formation in pharmacogenetics should be evaluated in naturally occurring systems with inherited alteration in encoded amino acid sequence...
  62. ncbi Pharmacogenomics: candidate gene identification, functional validation and mechanisms
    Liewei Wang
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics and Medicine, Mayo Medical School Mayo Clinic, Rochester, MN 55905, USA
    Hum Mol Genet 17:R174-9. 2008
    ....
  63. ncbi Human S-adenosylhomocysteine hydrolase: common gene sequence variation and functional genomic characterization
    Qiping Feng
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic Mayo Medical School, Rochester, Minnesota 55905, USA
    J Neurochem 110:1806-17. 2009
    ..These results represent a step toward understanding the functional consequences of common genetic variation in AHCY for the regulation of neurotransmitter, drug and macromolecule methylation...
  64. ncbi Methionine adenosyltransferase 2A/2B and methylation: gene sequence variation and functional genomics
    Kendra K S Nordgren
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Drug Metab Dispos 39:2135-47. 2011
    ..01. These observations provide a foundation for future mechanistic and clinical translational pharmacogenomic studies of MAT2A/2B...
  65. ncbi Human SULT1A1 gene: copy number differences and functional implications
    Scott J Hebbring
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hum Mol Genet 16:463-70. 2007
    ..0001). Overall, these observations have obvious implications for the effectiveness of SULT1A1 as a drug and hormone metabolizing enzyme and its potential role as a risk factor for disease...
  66. ncbi Catecholestrogen sulfation: possible role in carcinogenesis
    Araba A Adjei
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School-Mayo Clinic-Mayo Foundation, Rochester, Minnesota 55905, USA
    Biochem Biophys Res Commun 292:402-8. 2002
    ....
  67. ncbi N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis
    Elena Ricart
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Am J Gastroenterol 97:1763-8. 2002
    ..We determined the association between NAT1 genotype and response to mesalamine and sulfasalazine, as well as between NAT2 genotype and toxicity to sulfasalazine, in a population-based cohort of patients with ulcerative colitis...
  68. ncbi Primer on medical genomics. Part XII: Pharmacogenomics--general principles with cancer as a model
    Matthew P Goetz
    Department of Oncology Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:376-84. 2004
    ..Additionally, we discuss some of the ways in which physicians are currently applying this knowledge in the treatment of patients with cancer...
  69. ncbi Thiopurine S-methyltransferase pharmacogenetics: autophagy as a mechanism for variant allozyme degradation
    Fang Li
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic Mayo Medical School, Rochester, Minnesota 55905, USA
    Pharmacogenet Genomics 18:1083-94. 2008
    ..It also forms aggresomes, suggesting a possible dynamic balance between degradation and aggregation. We set out to identify genes encoding proteins participating in these processes...
  70. ncbi Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects
    Araba A Adjei
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Birth Defects Res A Clin Mol Teratol 82:155-65. 2008
    ..The purpose of this study was to characterize the variability of APAP sulfation in a panel of human fetal livers and to identify the sulfotransferases (SULT) isoform(s) responsible for catalyzing that activity...
  71. ncbi Pharmacogenomics: challenges and opportunities
    Dan M Roden
    Vanderbilt University, Nashville, Tennessee, USA
    Ann Intern Med 145:749-57. 2006
    ..Overcoming these challenges holds the promise of improving new drug development and ultimately individualizing the selection of appropriate drugs and dosages for individual patients...
  72. ncbi Pharmacogenomics and reducing the frequency of adverse drug events
    Richard M Weinshilboum
    Pharmacogenomics 4:1-4. 2003
  73. ncbi Metabolomics: a global biochemical approach to drug response and disease
    Rima Kaddurah-Daouk
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    Annu Rev Pharmacol Toxicol 48:653-83. 2008
    ..It also highlights potential metabolomic applications to pharmacology and clinical pharmacology...
  74. ncbi Thiopurine methyltransferase activity in red blood cells of dogs
    Linda Benjamin Kidd
    Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin Madison, Madison, WI, USA
    J Vet Intern Med 18:214-8. 2004
    ..0; P < .001) than did other breeds. Such variations in TPMT activity in the canine population and within groups of related dogs could affect thiopurine drug toxicity and efficacy in canine patients...
  75. ncbi The genomic revolution and medicine
    Richard M Weinshilboum
    Mayo Clin Proc 77:745-6. 2002
  76. ncbi Structural basis of substrate recognition in thiopurine s-methyltransferase
    Yi Peng
    Department of Biochemistry, Case Western Reserve University, Cleveland, Ohio 44106, USA
    Biochemistry 47:6216-25. 2008
    ....

Research Grants60

  1. INHERITED VARIATIONS IN DRUG METABOLIZING ENZYMES
    Richard Weinshilboum; Fiscal Year: 2009
    ..They will also help us understand role of the AdoMet-Methionine Cycle in individual variation in response to drug therapy, as well as its contribution to disease risk. ..
  2. Pharmacogenomics of cytosine arabinoside (Ara-C) and acute myelogenous leukemia
    Richard Weinshilboum; Fiscal Year: 2009
    ....
  3. INHERITED VARIATIONS IN DRUG METABOLIZING ENZYMES
    Richard M Weinshilboum; Fiscal Year: 2010
    ..They will also help us understand role of the AdoMet-Methionine Cycle in individual variation in response to drug therapy, as well as its contribution to disease risk. ..
  4. SULFATE CONJUGATION AND DRUG METABOLISM
    Richard Weinshilboum; Fiscal Year: 2003
    ....
  5. INHERITED VARIATIONS IN DRUG METABOLIZING ENZYMES
    Richard Weinshilboum; Fiscal Year: 2002
    ....
  6. Pharmacogenomics of cytosine arabinoside (Ara-C) and acute myelogenous leukemia
    Richard M Weinshilboum; Fiscal Year: 2010
    ....
  7. INHERITED VARIATIONS IN DRUG METABOLIZING ENZYMES
    Richard Weinshilboum; Fiscal Year: 2007
    ..They will also help us understand role of the AdoMet-Methionine Cycle in individual variation in response to drug therapy, as well as its contribution to disease risk. ..
  8. PHARMACOGENETICS OF PHASE II DRUG METABOLIZING ENZYMES
    Richard Weinshilboum; Fiscal Year: 2007
    ..All pharmacogenomic information obtained as a result of the research conducted by the Mayo PGRN will be rapidly deposited in the NIH-sponsored Pharm ..
  9. TRAINING GRANT IN CLINICAL PHARMACOLOGY
    Richard Weinshilboum; Fiscal Year: 2007
    ....
  10. SULFATE CONJUGATION AND DRUG METABOLISM
    Richard Weinshilboum; Fiscal Year: 2007
    ....
  11. INHERITED VARIATIONS IN DRUG METABOLIZING ENZYMES
    Richard Weinshilboum; Fiscal Year: 2006
    ....
  12. INHERITED VARIATIONS IN DRUG METABOLIZING ENZYMES
    Richard Weinshilboum; Fiscal Year: 1980
    ....
  13. SULFATE CONJUGATION AND DRUG METABOLISM
    Richard Weinshilboum; Fiscal Year: 1993
    ..The results of these studies will enhance our understanding of biological mechanisms responsible for individual variations in the sulfate conjugation of drugs, xenobiotics, neurotransmitters and hormones in humans...
  14. INHERITED VARIATIONS IN DRUG METABOLIZING ENZYMES
    Richard Weinshilboum; Fiscal Year: 1993
    ....